scholarly journals Will Zirconia Implants Replace Titanium Implants?

2021 ◽  
Vol 11 (15) ◽  
pp. 6776
Author(s):  
Liana Preto Webber ◽  
Hsun-Liang Chan ◽  
Hom-Lay Wang
Keyword(s):  
Soft Tissue ◽  
Clinical Results ◽  
Titanium Implants ◽  
Tissue Response ◽  
Advantages And Disadvantages ◽  
New Material ◽  
Soft Tissue Response ◽  
Zirconia Implants

This review aims to discuss the advantages and disadvantages of zirconia implants compared with titanium implants. Moreover, it intends to review the relevant available long-term literature of these two materials regarding osteointegration, soft-tissue, microbiota, and peri-implantitis, focusing on clinical results. Briefly, titanium implants are a reliable alternative for missing teeth; however, they are not incapable of failure. In an attempt to provide an alternative implant material, implants made from ceramic-derivate products were developed. Owing to its optimal osseointegration competence, biocompatibility, and esthetic proprieties, zirconium dioxide (ZrO2), also known as zirconia, has gained popularity among researchers and clinicians, being a metal-free alternative for titanium implants with its main use in the anterior esthetic zones. This type of implant may present similar osseointegration as those noted on titanium implants with a greater soft-tissue response. Furthermore, this material does not show corrosion as its titanium analog, and it is less susceptible to bacterial adhesion. Lastly, even presenting a similar inflammatory response to titanium, zirconia implants offer less biofilm formation, suggesting less susceptibility to peri-implantitis. However, it is a relatively new material that has been commercially available for a decade; consequently, the literature still lacks studies with long follow-up periods.

scholarly journals Long term evolution of soft tissue response in the fingers of high-level sport climbers: A cross-sectional 10 Year follow-up study

2021 ◽  
Vol 52 ◽  
pp. 173-179
Author(s):  
Stefan Fröhlich ◽  
Andreas Schweizer ◽  
Lisa Reissner ◽  
Tatjana Pastor ◽  
Jörg Spörri ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Long Term Evolution ◽  
Tissue Response ◽  
Cross Sectional ◽  
Follow Up Study ◽  
Term Evolution ◽  
Soft Tissue Response ◽  
High Level

scholarly journals Soft tissue response after Class III bimaxillary surgery

2012 ◽  
Vol 83 (3) ◽  
pp. 533-539 ◽  
Author(s):  
Gundega Jakobsone ◽  
Arild Stenvik ◽  
Lisen Espeland
Keyword(s):  
Soft Tissue ◽  
Tissue Response ◽  
Hard Tissue ◽  
Upper Lip ◽  
Short Term ◽  
Face Height ◽  
Soft Tissue Response ◽  
The Impact

ABSTRACT Objective: To analyze the impact of surgical change in anterior face height and skeletal relapse on the long-term soft tissue profile. Materials and Methods: Cephalometric radiographs of 81 patients taken before surgery and at five time points during a 3-year follow-up period were analyzed. All patients had Le Fort I and bilateral sagittal split osteotomies. The patients were divided into three subgroups according to the change in anterior face height during surgery. Calculations of soft to hard tissue ratios were based on the long-term soft tissue response relative to the surgical repositioning. Results: The horizontal surgical repositioning varied considerably, depending on whether anterior face height was increased or decreased. For upper lip prominence, the pattern of long-term change was the same irrespective of change in face height. In all groups, upper lip thickness decreased in both the short term and the long term, particularly in patients with surgical increase in face height. Lower lip thickness increased in the short term but decreased during the follow-up period. There were significant associations between horizontal soft tissue and corresponding hard tissue changes, except for soft tissue A-point and upper lip, when face height was increased. The ratios were higher for mandibular variables than for maxillary variables, particularly for B-point and pogonion when anterior face height had decreased. Conclusion: A change in facial height influences the soft tissue response. The mandibular soft tissues closely follow skeletal relapse beyond 2 months postsurgery. The findings have clinical implications for the relative maxillary and mandibular repositioning when planning surgery.

Controlled implant/soft tissue interaction by nanoscale surface modifications of 3D porous titanium implants

Nanoscale ◽  
2015 ◽  
Vol 7 (21) ◽  
pp. 9908-9918 ◽  
Author(s):  
Elisabeth Rieger ◽  
Agnès Dupret-Bories ◽  
Laetitia Salou ◽  
Marie-Helene Metz-Boutigue ◽  
Pierre Layrolle ◽  
...  
Keyword(s):  
Surface Modification ◽  
Soft Tissue ◽  
Surface Modifications ◽  
Porous Titanium ◽  
Titanium Implants ◽  
Tissue Response ◽  
Soft Tissue Response ◽  
Modification Of Titanium

Nanoscale surface modification of titanium microbeads can control the soft tissue response in vitro and in vivo.

Klinische Langzeitergebnisse der perkutanen transluminalen Angioplastie bei Patienten mit peripherer arterieller Verschlusskrankheit

VASA ◽  
2002 ◽  
Vol 31 (1) ◽  
pp. 36-42 ◽  
Author(s):  
. Bucek ◽  
Hudak ◽  
Schnürer ◽  
Ahmadi ◽  
Wolfram ◽  
...  
Keyword(s):  
Success Rate ◽  
Clinical Stage ◽  
Ankle Brachial Index ◽  
Clinical Situation ◽  
Clinical Results ◽  
Transluminal Angioplasty ◽  
Term Outcome ◽  
Long Term Outcome

Background: We investigated the long-term clinical results of percutaneous transluminal angioplasty (PTA) in patients with peripheral arterial occlusive disease (PAOD) and the influence of different parameters on the primary success rate, the rate of complications and the long-term outcome. Patients and methods: We reviewed clinical and hemodynamic follow-up data of 166 consecutive patients treated with PTA in 1987 in our department. Results: PTA improved the clinical situation in 79.4% of patients with iliac lesions and in 88.3% of patients with femoro-popliteal lesions. The clinical stage and ankle brachial index (ABI) post-interventional could be improved significantly (each P < 0,001), the same results were observed at the end of follow-up (each P < 0,001). Major complications occurred in 11 patients (6.6%). The rate of primary clinical long-term success for suprainguinal lesions was 55% and 38% after 5 and 10 years (femoro-popliteal 44% and 33%), respectively, the corresponding data for secondary clinical long-term success were 63% and 56% (60% and 55%). Older age (P = 0,017) and lower ABI pre-interventional (P = 0,019) significantly deteriorated primary clinical long-term success for suprainguinal lesions, while no factor could be identified influencing the outcome of femoro-popliteal lesions significantly. Conclusion: Besides an acceptable success rate with a low rate of severe complications, our results demonstrate favourable long-term clinical results of PTA in patients with PAOD.

Comparing the Responses of Osseous Versus Soft-Tissue Metastases of Renal Cell Carcinoma to Receptor Tyrosine Kinase Inhibitors and Immunotherapy

Kidney Cancer ◽  
2020 ◽  
Vol 4 (3) ◽  
pp. 151-158
Author(s):  
Katherine Yuxi Tai ◽  
Jad M. El Abiad ◽  
Carol D. Morris ◽  
Mark Christopher Markowski ◽  
Adam S. Levin
Keyword(s):  
Renal Cell Carcinoma ◽  
Soft Tissue ◽  
Cell Carcinoma ◽  
Receptor Tyrosine Kinase ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Tissue Response ◽  
Bone Response ◽  
Soft Tissue Response ◽  
Receptor Tyrosine Kinase Inhibitors

BACKGROUND: Checkpoint inhibitors and receptor tyrosine kinase inhibitors (RTKIs) have changed the standard of care for metastatic renal cell carcinoma (mRCC). Anecdotal evidence suggests these therapies may be less effective for treating bone than soft-tissue metastases. PURPOSE: We performed a retrospective review evaluating the relative clinical responses in soft-tissue and bone metastases in patients undergoing therapy using RTKIs and anti-programmed death-1 (PD-1) agents for mRCC. METHODS: Of the 2,212 patients in our institutional cancer registry with renal cell carcinoma (1997–2017), 68 (82 disease courses) were identified with measurable bone and soft-tissue metastases treated with RTKIs and/or PD-1s. Extent of metastasis was quantified at the time of therapy initiation (baseline) and at 3 months, 6 months, and 1 year. Changes in disease status were categorized as complete response, partial response, stable, mixed, or progression of disease according to RECIST v1.1 and MD Anderson criteria. These categories were further organized into “response to treatment” or “evidence of progression” to generate a generalized linear effects model with soft-tissue response as the independent variable and bone response as the dependent variable. Alpha = 0.05. RESULTS: Soft-tissue response correlated with bone response at 3 months (76 disease courses, p = 0.005) and 6 months (48 disease courses, p = 0.017). Of the patients with controlled soft-tissue disease, only 14 (19%) and 15 (32%) had progression in bone at 3 and 6 months, respectively. CONCLUSION: Contrary to anecdotal reports, osseous metastases do not appear to respond worse than soft-tissue metastases to treatment with these agents.

Sign in / Sign up

Export Citation Format

Share Document